Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation
Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation
复制标题
DOI：
10.1038/sj.bmt.1704061
复制
发表时间：
2003-06-01
影响因子：
4.8
通讯作者：
Zintl, F
中科院分区：
文献类型：
--
作者：
Gruhn, B;Meerbach, A;Zintl, F
EB 病毒 (EBV) 相关淋巴组织增生性疾病 (LPD) 是造血干细胞移植 (HSCT) 后危及生命的并发症。因此，EBV再激活的早期诊断和先发制人的治疗可能在临床上有用。我们报告了三名患者，其外周血单核细胞和血浆中 EBV 载量极高，但没有 EBV 疾病的证据。在使用单剂量利妥昔单抗进行先发制人治疗后，观察到 EBV 基因组拷贝和 B 淋巴细胞一致减少。所有三名患者均未发生 EBV 相关 LPD。我们的结论是，利妥昔单抗的先发性治疗似乎可以有效预防 HSCT 后发生 EBV 相关的 LPD。
Epstein - Barr virus (EBV)-associated lymphoproliferative disease (LPD) is a life-threatening complication following hematopoietic stem cell transplantation (HSCT). Therefore, early diagnosis of EBV reactivation and pre-emptive therapy may be clinically useful. We report three patients who presented with an extremely high EBV load in peripheral blood mononuclear cells and plasma without evidence of EBV disease. Following pre-emptive therapy with a single dose of rituximab, a concordant decrease of EBV-genome copies and B lymphocytes was observed. In all three patients, no EBV-associated LPD occurred. We conclude that pre-emptive therapy with rituximab appears to be effective for prevention of EBV-associated LPD after HSCT.